Products
Vixarelimab Biosimilar Monoclonal Antibody (OSMR) for Research
Pre-Made Vixarelimab biosimilar, Whole mAb, Anti-OSMR Antibody: Anti-IL-31R-beta/IL-31RB/OSMRB/OSMRbeta/PLCA1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vixarelimab is an investigational fully-human monoclonal antibody that targets OSMRβ, which mediates signaling of interleukin-31 (IL-31) and oncostatin M (OSM), two key cytokines implicated in pruritus, inflammation and fibrosis.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-623-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Vixarelimab biosimilar, Whole mAb, Anti-OSMR Antibody: Anti-IL-31R-beta/IL-31RB/OSMRB/OSMRbeta/PLCA1 therapeutic antibody |
| INN Name | Vixarelimab |
| Target | OSMR |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG4-G1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | na |
| Companies | Kiniksa Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Prurigo nodularis;Pruritus;Atopic dermatitis |
| Conditions Discontinued | na |
| Development Tech | na |
About target - OSMR
1. Protein Oncostatin-M-specific receptor subunit beta
2. Gene OSMR
3. Organism Homo sapiens (Human)
Function
Associates with IL31RA to form the IL31 receptor. Binds IL31 to activate STAT3 and possibly STAT1 and STAT5. Capable of transducing OSM-specific signaling events.
